KEYNOTE-042

NCT02220894 📎

Regimen

Experimental
pembrolizumab
Control
platinum doublet

Population

PD-L1≥1% advanced NSCLC 1L

Key finding

TPS≥50% mOS 20.0 vs 12.2 mo HR 0.69 (0.56-0.85); benefit driven by high expressors

Source: PMID 30955977

Timeline

  • Enrollment start: 2014-10-30 📎

Guideline citations

  • NCCN NSCLC Version 5.2026 (p.113)
  • CSCO NSCLC 2025 ⚠️ OCR source